Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.
about
Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cellsTriplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma.A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancerHuman Epidermal Growth Factor Receptor 2 (HER2/neu) in Salivary Gland Carcinomas: A Review of Literature.Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequent BAP1, PIK3CA, and other actionable genomic alterations.Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma.Molecular profiling of head and neck squamous cell carcinoma.Recent advances in the diagnostic pathology of salivary carcinomas.HER2 expression status in diverse cancers: review of results from 37,992 patients.Salivary Duct Carcinoma of the Parotid: Outcomes with a Contemporary Multidisciplinary Treatment Approach.Genomic landscape of salivary gland tumors.Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report.Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2.Cytogenetic and immunohistochemical biomarker profiling of therapy-relevant factors in salivary gland carcinomas.
P2860
Q33645792-36AD4BBD-8AC7-47A9-B191-76BC7546B4B4Q33787355-A847D580-185A-4896-85DF-C2859FC6AE96Q34436470-87204A26-61EF-40DE-B87C-A9C4B7AD86B3Q34978404-A4768073-F4EB-4EB5-9160-A58505593632Q35230643-DB1637EA-28AD-47E3-B35E-F247211431ACQ36317852-CC5C4FB1-25A7-47B4-9F54-BBDCBCA41F22Q37013995-5F5F68D3-C35B-4BC2-83EF-705094AAB4CBQ37337359-9393249D-6935-48DF-910E-EA5F8443947EQ38244735-04E0A721-EB0A-4892-875B-57ED1528C485Q38364900-C42A6C6D-B0E5-4ABA-A8E8-C71F52087E6EQ38776386-7379C963-4B5E-406E-A51F-6A7F15399ABEQ41546576-42541206-5290-4108-B805-31584C73F937Q42233857-E4F4212A-E2D5-4196-8F79-AF52D02C3321Q48123633-10C4631F-F908-482E-807D-31BE7FDE0E2CQ49511046-28980B9D-47CB-4B77-B0DF-B996903EEE9AQ50675747-73090E9E-3B07-43C7-AA12-A1B049BF3582
P2860
Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Human epidermal receptor 2-amp ...... factor combination treatment.
@en
Human epidermal receptor 2-amp ...... factor combination treatment.
@nl
type
label
Human epidermal receptor 2-amp ...... factor combination treatment.
@en
Human epidermal receptor 2-amp ...... factor combination treatment.
@nl
prefLabel
Human epidermal receptor 2-amp ...... factor combination treatment.
@en
Human epidermal receptor 2-amp ...... factor combination treatment.
@nl
P2093
P2860
P356
P1433
P1476
Human epidermal receptor 2-amp ...... factor combination treatment.
@en
P2093
Christel C Bastida
Gerald S Falchook
Scott M Lippman
P2860
P356
10.1002/HED.23429
P577
2013-10-19T00:00:00Z